Ida Fortini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ida Fortini has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Gabriel Taricani Kubota
Pain Center, Department of Neurology, University of São Paulo, São Paulo, Brazil
6 shared publications - Marcio Nattan Portes Souza
University of São Paulo
6 shared publications - Luiz Henrique Martins Castro
Department of Neurology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
5 shared publications - Marcia Rubia Rodrigues Gonçalves
Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Neurologia, São Paulo SP, Brazil
5 shared publications - Adalberto Studart-Neto
Universidade de São Paulo, Brazil
4 shared publications - Carlos Eduardo Borges Passos Neto
Universidade de São Paulo, Brazil
4 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by Headache Medicine in Headache Medicine
- Vol. 17 (2) , 98-110
Concordância entre única medida e a média de três medidas do limiar de dor por pressão craniofacial: viabilidade em adultos saudáveis.
BackgroundPressure pain threshold assessment is used to quantify pain sensitivity in headache disorders, reflecting peripheral and central sensitization of the nociceptive system. Traditional protocols involve multiple measurements to ensure reliability, but these protocols are time-consuming and may cause participant fatigue and discomfort. ObjectiveTo evaluate the agreement and reliability between a single Pressure Pain Threshold (PPT) measurement and the mean of three measurements in the craniofacial of individuals without a history of headache disorders, using a digital algometer. MethodsCross-sectional methodological study with ten volunteers (60% female, mean age 43±8 years) without headache history. Pressure pain threshold was assessed at eight craniofacial sites (bilateral: occipital, temporal, masseter; central: frontal, vertex) using a digital algometer. Three consecutive measurements were performed at each site with 10-minute intervals. Reliability between measurements was assessed using Intraclass Correlation Coefficient (ICC), while agreement and systematic bias were evaluated using Bland–Altman analysis. ResultsIntra-rater reliability ranged from moderate to good (ICC=0.54–0.96) across individual sites, with good-to-excellent reliability in bilateral occipital, temporal, and masseter sites (ICC=0.62–0.96). Reliability between the single measurement and the mean of three trials was uniformly excellent (ICC=0.93–0.98) Bland-Altman analysis showed minimal bias (mean differences near zero) and relatively narrow limits of agreement in peripheral sites, with wider limits observed in central regions.ConclusionA single pressure pain threshold measurement demonstrated agreement comparable to the mean of three measurements, supporting the potential use of simplified assessment protocols.
- 12 May 2026
- Published by Headache Medicine in Headache Medicine
- Vol. 17 (2) , 98-110
Open AccessConcordância entre única medida e a média de três medidas do limiar de dor por pressão craniofacial: viabilidade em adultos saudáveis.
BackgroundPressure pain threshold assessment is used to quantify pain sensitivity in headache disorders, reflecting peripheral and central sensitization of the nociceptive system. Traditional protocols involve multiple measurements to ensure reliability, but these protocols are time-consuming and may cause participant fatigue and discomfort. ObjectiveTo evaluate the agreement and reliability between a single Pressure Pain Threshold (PPT) measurement and the mean of three measurements in the craniofacial of individuals without a history of headache disorders, using a digital algometer. MethodsCross-sectional methodological study with ten volunteers (60% female, mean age 43±8 years) without headache history. Pressure pain threshold was assessed at eight craniofacial sites (bilateral: occipital, temporal, masseter; central: frontal, vertex) using a digital algometer. Three consecutive measurements were performed at each site with 10-minute intervals. Reliability between measurements was assessed using Intraclass Correlation Coefficient (ICC), while agreement and systematic bias were evaluated using Bland–Altman analysis. ResultsIntra-rater reliability ranged from moderate to good (ICC=0.54–0.96) across individual sites, with good-to-excellent reliability in bilateral occipital, temporal, and masseter sites (ICC=0.62–0.96). Reliability between the single measurement and the mean of three trials was uniformly excellent (ICC=0.93–0.98) Bland-Altman analysis showed minimal bias (mean differences near zero) and relatively narrow limits of agreement in peripheral sites, with wider limits observed in central regions.ConclusionA single pressure pain threshold measurement demonstrated agreement comparable to the mean of three measurements, supporting the potential use of simplified assessment protocols.
- Open Access
- 23 March 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (04) , 001-002
Metapneumovirus-associated necrotizing disseminated acute leukoencephalopathy
- 23 March 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (04) , 001-002
Open AccessMetapneumovirus-associated necrotizing disseminated acute leukoencephalopathy
- 3 January 2026
- Published by Springer Nature
- p. 491-502
Occipital Neuralgia
- Open Access
- 29 December 2025
- Published by Georg Thieme Verlag KG in Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery
- Vol. 44 (04) , e292-e297
Refractory Headache in Macroprolactinoma Resolved After Neurosurgery: A Challenging Clinical Case and Literature Review
Pituitary tumors are present in approximately 15% of the population and are often discovered incidentally during imaging for headache evaluation. Headaches are prevalent in patients with pituitary adenomas, occurring in 37-70% of cases. However, determining whether the tumor itself causes the pain is frequently challenging. A 27-year-old woman presented with progressive daily holocranial headaches, photophobia, phonophobia, nausea, and secondary amenorrhea. Laboratory tests and pituitary imaging confirmed a macroprolactinoma. Initial treatment with cabergoline and bromocriptine was unsuccessful due to intolerable side effects. Transsphenoidal surgery produced marked clinical improvement and a partial reduction in serum prolactin. However, tumor regrowth occurred with recurrence of daily headaches, and a second surgery was delayed due to the COVID-19 pandemic. Multiple medical treatments, which included topiramate, divalproex sodium, amitriptyline, propranolol, and riboflavin with magnesium resulted in no improvement. After the second neurosurgery, she presented normoprolactinemia with no residual tumor and once again a complete resolution of the headache episodes. Risk factors for headache related to adenoma include high prolactin or IGF-1 levels, cavernous sinus invasion (but not adenoma size), and a history of primary headache disorder. International diagnosis criteria emphasize headache resolution following endocrine normalization or tumor removal. This case highlights the intricate relationship between prolactinomas and headaches, underscoring the need for individualized treatment strategies.
- 29 December 2025
- Published by Georg Thieme Verlag KG in Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery
- Vol. 44 (04) , e292-e297
Open AccessRefractory Headache in Macroprolactinoma Resolved After Neurosurgery: A Challenging Clinical Case and Literature Review
Pituitary tumors are present in approximately 15% of the population and are often discovered incidentally during imaging for headache evaluation. Headaches are prevalent in patients with pituitary adenomas, occurring in 37-70% of cases. However, determining whether the tumor itself causes the pain is frequently challenging. A 27-year-old woman presented with progressive daily holocranial headaches, photophobia, phonophobia, nausea, and secondary amenorrhea. Laboratory tests and pituitary imaging confirmed a macroprolactinoma. Initial treatment with cabergoline and bromocriptine was unsuccessful due to intolerable side effects. Transsphenoidal surgery produced marked clinical improvement and a partial reduction in serum prolactin. However, tumor regrowth occurred with recurrence of daily headaches, and a second surgery was delayed due to the COVID-19 pandemic. Multiple medical treatments, which included topiramate, divalproex sodium, amitriptyline, propranolol, and riboflavin with magnesium resulted in no improvement. After the second neurosurgery, she presented normoprolactinemia with no residual tumor and once again a complete resolution of the headache episodes. Risk factors for headache related to adenoma include high prolactin or IGF-1 levels, cavernous sinus invasion (but not adenoma size), and a history of primary headache disorder. International diagnosis criteria emphasize headache resolution following endocrine normalization or tumor removal. This case highlights the intricate relationship between prolactinomas and headaches, underscoring the need for individualized treatment strategies.
- Open Access
- 27 October 2022
- Published by Headache Medicine in Headache Medicine
- p. 20
Intra-rater reliability of pressure pain threshold using a digital algometer
Background Pressure Pain Thresholds (PPT) has been the main sensory modality studied in headache disorders. It is usually repetitive, leading to potential variability between measurements. Since threshold estimation relies on the observer, patient, body site, and the device used, it is important to assess measurement reliability in the specific clinical and methodological scenario to be studied in order to minimize error. Objective The aim of this study is to confirm intra-rater reliability of PPT in the head of adults using a digital algometer device. Methods PPT was measured with a digital algometer in 3 consecutive assessments conducted 10 min apart. Eight sites were measured in each time at the occipital, temporal and masseter regions bilaterally, frontal and vertex at midline. The reliability using intra-class variability (ICC) and covariance were calculated between times 1, 2, 3, and all times versus the mean. Scores above 0,75 were considered as having excellent reliability. Results Ten healthy volunteers aged (21-55) were studied. The sum of all sites measured in the head was 2182 (+-672) KPa for the first measure, 2085 (+- 626) KPa for the second, 2185 (+-685) for the third, and 2150 (+-685) KPa for the mean. All ICC coefficients calculated were 0,975 or higher in all areas. Conclusions We concluded that one PPT measure in the head with a digital algometer is as reliable as 3 repetitive measures The intra-rater reliability for PPT is considered excellent. Future studies assessing pain vulnerability or predicting headache occurrence can be performed without a significant risk of bias. Keywords: Pressure PainThreshold, Algometry, Reliability, Intra-class.
- 27 October 2022
- Published by Headache Medicine in Headache Medicine
- p. 20
Open AccessIntra-rater reliability of pressure pain threshold using a digital algometer
Background Pressure Pain Thresholds (PPT) has been the main sensory modality studied in headache disorders. It is usually repetitive, leading to potential variability between measurements. Since threshold estimation relies on the observer, patient, body site, and the device used, it is important to assess measurement reliability in the specific clinical and methodological scenario to be studied in order to minimize error. Objective The aim of this study is to confirm intra-rater reliability of PPT in the head of adults using a digital algometer device. Methods PPT was measured with a digital algometer in 3 consecutive assessments conducted 10 min apart. Eight sites were measured in each time at the occipital, temporal and masseter regions bilaterally, frontal and vertex at midline. The reliability using intra-class variability (ICC) and covariance were calculated between times 1, 2, 3, and all times versus the mean. Scores above 0,75 were considered as having excellent reliability. Results Ten healthy volunteers aged (21-55) were studied. The sum of all sites measured in the head was 2182 (+-672) KPa for the first measure, 2085 (+- 626) KPa for the second, 2185 (+-685) for the third, and 2150 (+-685) KPa for the mean. All ICC coefficients calculated were 0,975 or higher in all areas. Conclusions We concluded that one PPT measure in the head with a digital algometer is as reliable as 3 repetitive measures The intra-rater reliability for PPT is considered excellent. Future studies assessing pain vulnerability or predicting headache occurrence can be performed without a significant risk of bias. Keywords: Pressure PainThreshold, Algometry, Reliability, Intra-class.
- Open Access
- 1 September 2022
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 80 (09) , 953-969
Consensus of the Brazilian Headache Society (SBCe) for prophylactic treatment of episodic migraine: part II
Background Migraine affects 1 billion people worldwide and > 30 million Brazilians; besides, it is an underdiagnosed and undertreated disorder.Objective The need to disseminate knowledge about the prophylactic treatment of migraine is known, so the Brazilian Headache Society (SBCe, in the Portuguese acronym) appointed a committee of authors with the objective of establishing a consensus with recommendations on the prophylactic treatment of episodic migraine based on articles from the world literature as well as from personal experience.Methods Meetings were held entirely online, with the participation of 12 groups that reviewed and wrote about the pharmacological categories of drugs and, at the end, met to read and finish the document. The drug classes studied in part II of this Consensus were: antihypertensives, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, calcium channel blockers, other drugs, and rational polytherapy.Results From this list of drugs, only candesartan has been established as effective in controlling episodic migraine. Flunarizine, venlafaxine, duloxetine, and pizotifen were defined as likely to be effective, while lisinopril, enalapril, escitalopram, fluvoxamine, quetiapine, atorvastatin, simvastatin, cyproheptadine, and melatonin were possibly effective in prophylaxis of the disease.Conclusions Despite an effort by the scientific community to find really effective drugs in the treatment of migraine, given the large number of drugs tested for this purpose, we still have few therapeutic options.
- 1 September 2022
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 80 (09) , 953-969
Open AccessConsensus of the Brazilian Headache Society (SBCe) for prophylactic treatment of episodic migraine: part II
Background Migraine affects 1 billion people worldwide and > 30 million Brazilians; besides, it is an underdiagnosed and undertreated disorder.Objective The need to disseminate knowledge about the prophylactic treatment of migraine is known, so the Brazilian Headache Society (SBCe, in the Portuguese acronym) appointed a committee of authors with the objective of establishing a consensus with recommendations on the prophylactic treatment of episodic migraine based on articles from the world literature as well as from personal experience.Methods Meetings were held entirely online, with the participation of 12 groups that reviewed and wrote about the pharmacological categories of drugs and, at the end, met to read and finish the document. The drug classes studied in part II of this Consensus were: antihypertensives, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, calcium channel blockers, other drugs, and rational polytherapy.Results From this list of drugs, only candesartan has been established as effective in controlling episodic migraine. Flunarizine, venlafaxine, duloxetine, and pizotifen were defined as likely to be effective, while lisinopril, enalapril, escitalopram, fluvoxamine, quetiapine, atorvastatin, simvastatin, cyproheptadine, and melatonin were possibly effective in prophylaxis of the disease.Conclusions Despite an effort by the scientific community to find really effective drugs in the treatment of migraine, given the large number of drugs tested for this purpose, we still have few therapeutic options.
- Open Access
- 1 August 2022
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 80 (08) , 845-861
Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I
The Brazilian Headache Society (Sociedade Brasileira de Cefaleia, SBCe, in Portuguese) nominated a Committee of Authors with the aim of establishing a consensus with recommendations regarding prophylactic treatment for episodic migraine based on articles published in the worldwide literature, as well as personal experience. Migraine affects 1 billion people around the world and more than 30 million Brazilians. In addition, it is an underdiagnosed and undertreated disorder. It is well known within the medical community of neurologists, and especially among headache specialists, that there is a need to disseminate knowledge about prophylactic treatment for migraine. For this purpose, together with the need for drug updates and to expand knowledge of the disease itself (frequency, intensity, duration, impact and perhaps the progression of migraine), this Consensus was developed, following a full online methodology, by 12 groups who reviewed and wrote about the pharmacological categories of the drugs used and, at the end of the process, met to read and establish conclusions for this document. The drug classes studied were: anticonvulsants, tricyclic antidepressants, monoclonal anti-calcitonin gene-related peptide (anti-CGRP) antibodies, beta-blockers, antihypertensives, calcium channel inhibitors, other antidepressants (selective serotonin reuptake inhibitors, SSRIs, and dual-action antidepressants), other drugs, and polytherapy. Hormonal treatment and anti-inflammatories and triptans in minimum prophylaxis schemes (miniprophylaxis) will be covered in a specific chapter. The drug classes studied for part I of the Consensus were: anticonvulsants, tricyclic antidepressants, monoclonal anti-CGRP antibodies, and beta-blockers.
- 1 August 2022
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 80 (08) , 845-861
Open AccessConsensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I
The Brazilian Headache Society (Sociedade Brasileira de Cefaleia, SBCe, in Portuguese) nominated a Committee of Authors with the aim of establishing a consensus with recommendations regarding prophylactic treatment for episodic migraine based on articles published in the worldwide literature, as well as personal experience. Migraine affects 1 billion people around the world and more than 30 million Brazilians. In addition, it is an underdiagnosed and undertreated disorder. It is well known within the medical community of neurologists, and especially among headache specialists, that there is a need to disseminate knowledge about prophylactic treatment for migraine. For this purpose, together with the need for drug updates and to expand knowledge of the disease itself (frequency, intensity, duration, impact and perhaps the progression of migraine), this Consensus was developed, following a full online methodology, by 12 groups who reviewed and wrote about the pharmacological categories of the drugs used and, at the end of the process, met to read and establish conclusions for this document. The drug classes studied were: anticonvulsants, tricyclic antidepressants, monoclonal anti-calcitonin gene-related peptide (anti-CGRP) antibodies, beta-blockers, antihypertensives, calcium channel inhibitors, other antidepressants (selective serotonin reuptake inhibitors, SSRIs, and dual-action antidepressants), other drugs, and polytherapy. Hormonal treatment and anti-inflammatories and triptans in minimum prophylaxis schemes (miniprophylaxis) will be covered in a specific chapter. The drug classes studied for part I of the Consensus were: anticonvulsants, tricyclic antidepressants, monoclonal anti-CGRP antibodies, and beta-blockers.
- Open Access
- 1 May 2022
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 80 (5 suppl 1) , 227-231
Update on Idiopathic Intracranial Hypertension Management
Background: Idiopathic Intracranial Hypertension (IIH) is a secondary headache with a steadily growing incidence. Currently, there is little evidence to guide the treatment of IIH. Objective: To review the pathophysiology of IIH, with focus on the role of obesity as a risk factor, and the implications for new therapeutic perspectives. Methods: in this narrative review, we summarized the current knowledge on treatment options highlighting available evidence for managing intracranial hypertension, obesity, and headache. Results: Clinical Presentation: headache is the most common symptom and a significant cause of quality-of-life impairment. Visual loss is common in the diagnosis. Pathophysiology: there is no unified theory able to explain all symptoms and the evolution of the disease. There is growing data pointing to metabolic changes and obesity with a central role in IIH pathophysiology. Treatment: most published data on IIH treatment is related to pressure control and protection from visual loss. Acetazolamide and cerebrospinal fluid diversion are the best options available. Optic nerve sheath fenestration might be useful to temporally control the pressure over the optic nerve and thus protect from visual deterioration. Recently, venous sinus stenting has proven to be a safe option in selected cases. Finally, bariatric surgery has proven to effectively control elevated intracranial pressure. Conclusion: IIH is a potential cause of high disability. Early recognition is important, and treatment should be tailored to the needs of each case. There is a lack of research on headache management, which might persist after ICP control.
- 1 May 2022
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 80 (5 suppl 1) , 227-231
Open AccessUpdate on Idiopathic Intracranial Hypertension Management
Background: Idiopathic Intracranial Hypertension (IIH) is a secondary headache with a steadily growing incidence. Currently, there is little evidence to guide the treatment of IIH. Objective: To review the pathophysiology of IIH, with focus on the role of obesity as a risk factor, and the implications for new therapeutic perspectives. Methods: in this narrative review, we summarized the current knowledge on treatment options highlighting available evidence for managing intracranial hypertension, obesity, and headache. Results: Clinical Presentation: headache is the most common symptom and a significant cause of quality-of-life impairment. Visual loss is common in the diagnosis. Pathophysiology: there is no unified theory able to explain all symptoms and the evolution of the disease. There is growing data pointing to metabolic changes and obesity with a central role in IIH pathophysiology. Treatment: most published data on IIH treatment is related to pressure control and protection from visual loss. Acetazolamide and cerebrospinal fluid diversion are the best options available. Optic nerve sheath fenestration might be useful to temporally control the pressure over the optic nerve and thus protect from visual deterioration. Recently, venous sinus stenting has proven to be a safe option in selected cases. Finally, bariatric surgery has proven to effectively control elevated intracranial pressure. Conclusion: IIH is a potential cause of high disability. Early recognition is important, and treatment should be tailored to the needs of each case. There is a lack of research on headache management, which might persist after ICP control.
- Open Access
- 1 May 2022
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 80 (5 suppl 1) , 204-213
Headaches and obesity
Obesity and headache disorders are two very common conditions in the general population that have been increasing in incidence over the last decades. Recent studies have shown a significant relationship between obesity and headaches, particularly migraine, with an important role in whether the disease is chronic. On the other hand, no such association was found with tension-type headaches. Studies showing an overlapping of hunger-control pathways and those involved in the pathophysiology of migraine may justify the close association between obesity and migraine. Moreover, a secondary headache for which obesity is a strong risk factor is idiopathic Intracranial Hypertension (pseudotumor cerebri), with several studies showing the impact of weight reduction/bariatric surgery in the treatment of the disease. In conclusion, since obesity is a modifiable risk factor, it is important for physicians treating patients with headaches, and particularly migraine, to be aware of the association between these two disorders.
- 1 May 2022
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 80 (5 suppl 1) , 204-213
Open AccessHeadaches and obesity
Obesity and headache disorders are two very common conditions in the general population that have been increasing in incidence over the last decades. Recent studies have shown a significant relationship between obesity and headaches, particularly migraine, with an important role in whether the disease is chronic. On the other hand, no such association was found with tension-type headaches. Studies showing an overlapping of hunger-control pathways and those involved in the pathophysiology of migraine may justify the close association between obesity and migraine. Moreover, a secondary headache for which obesity is a strong risk factor is idiopathic Intracranial Hypertension (pseudotumor cerebri), with several studies showing the impact of weight reduction/bariatric surgery in the treatment of the disease. In conclusion, since obesity is a modifiable risk factor, it is important for physicians treating patients with headaches, and particularly migraine, to be aware of the association between these two disorders.